HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder.

AbstractBACKGROUND:
This study develops an economic model to evaluate the cost-effectiveness of ethyl-eicosapentaenoic acid (ethyl-EPA) as an adjunct treatment of bipolar I disorder.
METHODS:
A 1-year Markov model is used incorporating three health states: euthymic, manic and depressive. The model was populated using outcomes from a clinical trial on clinical efficacy and other published literature.
RESULTS:
The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) of ethyl-EPA in comparison with placebo was estimated to be -£2,782 in 2008/09 prices, the negative ICER indicating ethyl-EPA to be a more effective and less costly treatment option than placebo in terms of cost savings of other resource use.
CONCLUSIONS:
The sensitivity analysis indicated that the results were robust. Future research covering a longer time period using broader costs of the disease will be required to consolidate these findings.
AuthorsNadir Cheema, Sophia Frangou, Paul McCrone
JournalTherapeutic advances in psychopharmacology (Ther Adv Psychopharmacol) Vol. 3 Issue 2 Pg. 73-81 (Apr 2013) ISSN: 2045-1253 [Print] England
PMID24167678 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: